PMC:7558914 / 2115-4367
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"80","span":{"begin":112,"end":159},"obj":"Species"},{"id":"81","span":{"begin":161,"end":171},"obj":"Species"},{"id":"82","span":{"begin":43,"end":68},"obj":"Disease"},{"id":"83","span":{"begin":75,"end":83},"obj":"Disease"},{"id":"84","span":{"begin":398,"end":404},"obj":"Disease"},{"id":"85","span":{"begin":406,"end":415},"obj":"Disease"},{"id":"86","span":{"begin":637,"end":643},"obj":"Disease"},{"id":"87","span":{"begin":659,"end":665},"obj":"Disease"},{"id":"91","span":{"begin":759,"end":769},"obj":"Species"},{"id":"92","span":{"begin":887,"end":897},"obj":"Species"},{"id":"93","span":{"begin":1153,"end":1161},"obj":"Species"},{"id":"97","span":{"begin":1284,"end":1291},"obj":"Species"},{"id":"98","span":{"begin":1977,"end":1985},"obj":"Disease"},{"id":"99","span":{"begin":2028,"end":2037},"obj":"Disease"}],"attributes":[{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"Tax:2697049"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:2697049"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"MESH:C000657245"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"MESH:C000657245"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"MESH:D003643"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:D003643"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:D003643"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"Tax:2697049"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"Tax:2697049"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"Tax:9606"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Tax:9606"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"1. Introduction\nThe global pandemic of the novel coronavirus disease 2019 (COVID-19) caused by a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly recognized in Wuhan (China) in December 2019. It quickly became a global pandemic, spreading worldwide [1]. Spain is one of the most affected countries, with more than 593,000 confirmed cases and more than 29,700 deaths. Andalusia—one of the 17 autonomous communities of Spain and the most populous of them, with a total population of over eight million—has officially registered around 42,640 cases (7.2% of total confirmed cases nationwide) and 1552 deaths (5.2% of total deaths nationwide) [2].\nCurrently, efficacy has not been fully established for any drug therapy for SARS-CoV-2. Several agents are being used in clinical trials and compassionate-use protocols based on in vitro activity against SARS-CoV-2 or related viruses, and on limited clinical experience [3]. Early detection and optimized supportive care to relieve symptoms and support organ function in more severe presentations are the mainstay of management. Where possible, moderate to severely ill patients should be managed in a hospital setting [4].\nThere are hundreds of clinical protocols around the world adapted locally to patient characteristics, prevention measures, diagnostic tests, availability of potential therapy options, and possibility of follow-up. The use of clinical protocols in health care aims to provide practitioners with locally agreed information about what is currently the recommended approach for a specific practice. Such protocols should be systematically developed and based on an evaluation of the current best evidence. Thus, they also have the potential advantage of reducing unnecessary variations in care and contributing to evidence-based health care [5]. Based on this premise, we conducted this study, whose main objective was to compare updated clinical protocols for treatment of COVID-19 among the largest university hospitals in Andalusia, Spain. We hypothesized that clinical protocols could vary in several aspects among Andalusian Hospitals, regardless of whether they belong to the same local health system administration and have similar resources."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T17","span":{"begin":0,"end":2},"obj":"Sentence"},{"id":"T18","span":{"begin":3,"end":15},"obj":"Sentence"},{"id":"T19","span":{"begin":16,"end":230},"obj":"Sentence"},{"id":"T20","span":{"begin":231,"end":292},"obj":"Sentence"},{"id":"T21","span":{"begin":293,"end":405},"obj":"Sentence"},{"id":"T22","span":{"begin":406,"end":682},"obj":"Sentence"},{"id":"T23","span":{"begin":683,"end":770},"obj":"Sentence"},{"id":"T24","span":{"begin":771,"end":957},"obj":"Sentence"},{"id":"T25","span":{"begin":958,"end":1111},"obj":"Sentence"},{"id":"T26","span":{"begin":1112,"end":1206},"obj":"Sentence"},{"id":"T27","span":{"begin":1207,"end":1420},"obj":"Sentence"},{"id":"T28","span":{"begin":1421,"end":1601},"obj":"Sentence"},{"id":"T29","span":{"begin":1602,"end":1708},"obj":"Sentence"},{"id":"T30","span":{"begin":1709,"end":1848},"obj":"Sentence"},{"id":"T31","span":{"begin":1849,"end":2045},"obj":"Sentence"},{"id":"T32","span":{"begin":2046,"end":2252},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"1. Introduction\nThe global pandemic of the novel coronavirus disease 2019 (COVID-19) caused by a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly recognized in Wuhan (China) in December 2019. It quickly became a global pandemic, spreading worldwide [1]. Spain is one of the most affected countries, with more than 593,000 confirmed cases and more than 29,700 deaths. Andalusia—one of the 17 autonomous communities of Spain and the most populous of them, with a total population of over eight million—has officially registered around 42,640 cases (7.2% of total confirmed cases nationwide) and 1552 deaths (5.2% of total deaths nationwide) [2].\nCurrently, efficacy has not been fully established for any drug therapy for SARS-CoV-2. Several agents are being used in clinical trials and compassionate-use protocols based on in vitro activity against SARS-CoV-2 or related viruses, and on limited clinical experience [3]. Early detection and optimized supportive care to relieve symptoms and support organ function in more severe presentations are the mainstay of management. Where possible, moderate to severely ill patients should be managed in a hospital setting [4].\nThere are hundreds of clinical protocols around the world adapted locally to patient characteristics, prevention measures, diagnostic tests, availability of potential therapy options, and possibility of follow-up. The use of clinical protocols in health care aims to provide practitioners with locally agreed information about what is currently the recommended approach for a specific practice. Such protocols should be systematically developed and based on an evaluation of the current best evidence. Thus, they also have the potential advantage of reducing unnecessary variations in care and contributing to evidence-based health care [5]. Based on this premise, we conducted this study, whose main objective was to compare updated clinical protocols for treatment of COVID-19 among the largest university hospitals in Andalusia, Spain. We hypothesized that clinical protocols could vary in several aspects among Andalusian Hospitals, regardless of whether they belong to the same local health system administration and have similar resources."}